IDEXX Laboratories (NASDAQ:IDXX) Announces Quarterly Earnings Results

IDEXX Laboratories (NASDAQ:IDXX) issued its quarterly earnings data on Monday. The company reported $3.08 EPS for the quarter, topping analysts’ consensus estimates of $2.93 by $0.15, Briefing.com reports. The company had revenue of $1.09 billion for the quarter, compared to analysts’ expectations of $1.07 billion. IDEXX Laboratories had a return on equity of 67.78% and a net margin of 24.65%.The firm’s quarterly revenue was up 14.3% on a year-over-year basis. During the same quarter in the previous year, the firm posted $2.53 earnings per share. IDEXX Laboratories updated its FY 2026 guidance to 14.290-14.800 EPS.

Here are the key takeaways from IDEXX Laboratories’ conference call:

• IDEXX delivered strong results with Q4 revenue up 14% reported / 12% organic, full?year organic revenue +10%, Q4 EPS of $3.08 (+17% comparable) and record premium instrument placements including nearly 6,400 inVue Dx and a ~78,000 Catalyst install base.
• Management provided 2026 guidance of $4.632B–$4.72B in revenue (?7%–9% organic), targeted 8%–10% organic growth in CAG Diagnostics recurring revenue, and EPS of $14.29–$14.80 (?10%–14% comparable growth).
• Demand headwinds persist as U.S. same?store clinical visits remain down (?-1.7% Q4, -1.9% FY2025), company plans for ?-2% visit declines in 2026, and Rapid Assay revenue fell ~3% in Q4 partly from transitioning pancreatic lipase to Catalyst (?4% headwind).
• Innovation momentum is a key growth driver — inVue Dx contributed >$75M of instrument revenue in 2025 with a planned ~5,500 placements in 2026, Cancer Dx will add mast cell tumor detection mid?2026, and Catalyst menu expansions plus software (Vello, cloud PIMS) are lifting consumables and utilization.
• Financial flexibility remains strong with 2025 free cash flow of $1.1B (100% of net income), $1.2B of share repurchases (2.4M shares), low leverage (~0.5x gross), and 2026 guidance for ~85%–95% net income?to?FCF conversion with capex of ~$180M.

IDEXX Laboratories Stock Performance

IDXX traded down $13.28 during midday trading on Monday, reaching $657.18. The company had a trading volume of 107,446 shares, compared to its average volume of 453,026. The business has a 50-day moving average price of $705.35 and a two-hundred day moving average price of $661.79. The stock has a market cap of $52.48 billion, a PE ratio of 51.25, a P/E/G ratio of 3.58 and a beta of 1.67. The company has a debt-to-equity ratio of 0.24, a quick ratio of 0.87 and a current ratio of 1.18. IDEXX Laboratories has a 12-month low of $356.14 and a 12-month high of $769.98.

Analyst Upgrades and Downgrades

IDXX has been the topic of several analyst reports. JPMorgan Chase & Co. upped their target price on IDEXX Laboratories from $675.00 to $775.00 and gave the stock an “overweight” rating in a report on Tuesday, November 4th. Wall Street Zen lowered IDEXX Laboratories from a “strong-buy” rating to a “buy” rating in a research note on Saturday, January 17th. Barclays began coverage on shares of IDEXX Laboratories in a research report on Monday, December 8th. They set an “overweight” rating and a $850.00 price objective on the stock. Weiss Ratings lowered IDEXX Laboratories from a “buy (b-)” rating to a “hold (c+)” rating in a research report on Thursday. Finally, Morgan Stanley increased their target price on IDEXX Laboratories from $765.00 to $805.00 and gave the company an “overweight” rating in a research report on Tuesday, November 4th. Seven equities research analysts have rated the stock with a Buy rating and four have assigned a Hold rating to the company. According to data from MarketBeat, IDEXX Laboratories presently has an average rating of “Moderate Buy” and a consensus price target of $763.50.

Insider Buying and Selling

In other IDEXX Laboratories news, EVP Nimrata Hunt sold 9,425 shares of the business’s stock in a transaction that occurred on Friday, November 7th. The stock was sold at an average price of $703.34, for a total transaction of $6,628,979.50. Following the completion of the transaction, the executive vice president owned 21,149 shares in the company, valued at $14,874,937.66. The trade was a 30.83% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Corporate insiders own 0.98% of the company’s stock.

Institutional Investors Weigh In On IDEXX Laboratories

Several hedge funds have recently modified their holdings of the stock. Empowered Funds LLC increased its stake in shares of IDEXX Laboratories by 6.6% during the 1st quarter. Empowered Funds LLC now owns 1,538 shares of the company’s stock worth $646,000 after purchasing an additional 95 shares during the last quarter. Sivia Capital Partners LLC bought a new position in shares of IDEXX Laboratories in the second quarter worth $265,000. Jump Financial LLC grew its stake in shares of IDEXX Laboratories by 1,006.4% during the second quarter. Jump Financial LLC now owns 5,532 shares of the company’s stock valued at $2,967,000 after buying an additional 5,032 shares during the last quarter. Cary Street Partners Financial LLC bought a new stake in IDEXX Laboratories during the 2nd quarter valued at approximately $164,000. Finally, Sei Investments Co. raised its stake in shares of IDEXX Laboratories by 218.7% in the second quarter. Sei Investments Co. now owns 120,587 shares of the company’s stock worth $64,678,000 after purchasing an additional 82,755 shares during the last quarter. 87.84% of the stock is owned by institutional investors and hedge funds.

IDEXX Laboratories Company Profile

IDEXX Laboratories, Inc (NASDAQ: IDXX) is a global developer, manufacturer and provider of diagnostic products and services primarily for the animal health, water testing and food safety markets. Headquartered in Westbrook, Maine, the company supplies in-clinic diagnostic instruments, consumables, reference laboratory testing and practice-management tools that support veterinarians, livestock and dairy producers, and utilities and food producers worldwide.

IDEXX’s product portfolio includes point-of-care tests and immunoassays designed for rapid diagnosis in veterinary clinics, in-clinic chemistry and hematology analyzers, automated urinalysis systems, and digital diagnostic solutions.